Beam Therapeutics Inc. (BEAM) financial statements and ratios from SEC XBRL: revenue $139.74M (TTM), net margin -57.2%, revenue growth 120.0% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (TTM) | $139.74M |
| Net Margin | -57.2% |
| Revenue Growth (YoY) | 120.0% |
| EPS Growth (YoY) | -82.3% |
| FCF Growth (YoY) | 1.1% |
| Price / Book | 2.75 |
| Price / Sales | 39.81 |
| FCF Yield | -25.0% |
| Altman Z-Score | 5.78 (safe) |
| Sector P/E (Healthcare) | 21.6 |
BEAM overview · BEAM earnings · BEAM KPIs · BEAM investor relations · BEAM ownership · BEAM peers · BEAM filings
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.